HPGD

Chr 4q34.1

15-hydroxyprostaglandin dehydrogenase

Aliases:: SDR36C1
MANE:: ENST00000296522.11

OMIM: 601688 ↗NCBI: 3248 ↗Ensembl ↗

Annotations refreshed 1 month ago.

Predicted protein structure

AlphaFold predicted structure

HPGD · P15428

v62025-08-01

Predicted Aligned Error matrix for HPGD — diagonal shows residue index, colour shows pairwise prediction confidence (lower is better) — Predicted Aligned Error

Mean pLDDT

96.9/ 100

Very high

266 residues

Confidence breakdown

Very high(≥ 90)96%
Confident(70–90)2%
Low(50–70)2%
Very low(< 50)0%

Open interactive 3D viewer

AlphaFold (Jumper et al., 2021) · CC BY 4.0

Clinical relevance (Genomics England PanelApp)

Diagnostic Grade (Green)

Autosomal recessive primary hypertrophic osteoarthropathy
BIALLELIC, autosomal or pseudoautosomal
DDG2P
BIALLELIC, autosomal or pseudoautosomal
Skeletal dysplasia
BOTH monoallelic and biallelic, autosomal or pseudoautosomal
Fetal anomalies
BIALLELIC, autosomal or pseudoautosomal
Intellectual disability
BIALLELIC, autosomal or pseudoautosomal

Disease associations (Open Targets)

hypertrophic osteoarthropathy, primary, autosomal recessive, 1
0.75
cranio-osteoarthropathy
0.71
isolated congenital digital clubbing
0.68
Pachydermoperiostosis
0.62
hereditary disease
0.19
dyshidrosis
0.15
ovarian neoplasm
0.13
placenta praevia
0.13
hepatocellular carcinoma
0.11
Varicose veins
0.10

Score is the Open Targets composite evidence score (0-1). Higher = stronger gene-disease association.

Protein function (UniProt)

15-hydroxyprostaglandin dehydrogenase [NAD(+)]

Catalyzes the NAD-dependent dehydrogenation (oxidation) of a broad array of hydroxylated polyunsaturated fatty acids (mainly eicosanoids and docosanoids, including prostaglandins, lipoxins and resolvins), yielding their corresponding keto (oxo) metabolites (PubMed:10837478, PubMed:16757471, PubMed:16828555, PubMed:21916491, PubMed:25586183, PubMed:8086429). Decreases the levels of the pro-proliferative prostaglandins such as prostaglandin E2 (whose activity is increased in cancer because of an increase in the expression of cyclooxygenase 2) and generates oxo-fatty acid products that can profoundly influence cell function by abrogating pro-inflammatory cytokine expression (PubMed:15574495, PubMed:25586183). Converts resolvins E1, D1 and D2 to their oxo products, which represents a mode of resolvin inactivation. Resolvin E1 plays important roles during the resolution phase of acute inflammation, while resolvins D1 and D2 have a unique role in obesity-induced adipose inflammation (PubMed:16757471, PubMed:22844113)